Eli Lilly Just Added Another Potential Billion-Dollar Product: Is It a Buy?
Investors looking for a stock that has crushed the market this year need look no further than pharmaceutical giant Eli Lilly (NYSE: LLY). The drugmaker has been on a tear on the back of excellent financial results and solid clinical progress. However, Eli Lilly has, so far, failed to accomplish some of the goals it set out for itself for 2023. Some of the treatments it aimed to launch have encountered regulatory obstacles.
Thankfully, these issues haven't slowed Eli Lilly, and the company is working to resolve them. Case in point: It recently earned approval for a medicine that was initially rejected by the Food and Drug Administration (FDA).
Source Fool.com